Kornimate/medical-research-clean huggingface dataset:
ticagrelor antiplatelet therapy to reduce graft events and thrombosis

Conditions: Saphenous Vein Graft Disease

Summary: saphenous vein graft disease remains an unresolved medical problem. many vein grafts occlude in the first year after bypass surgery, leading to adverse cardiovascular outcomes, including recurrent angina, myocardial infarction, and the need for repeat coronary intervention. while aspirin is the standard antiplatelet treatment after cabg surgery, 10-20% of vein grafts continue to occlude despite contemporary secondary preventative therapy. compared to aspirin and other antiplatelet therapies like clopidogrel, ticagrelor treatment leads to a more pronounced platelet inhibition, and may substantially improve graft patency following cabg compared to aspirin. no data has yet to be collected regarding the impact of ticagrelor on saphenous vein graft patency following cabg. in this context, the investigators seek to compare vein graft patency between patients randomized to receive aspirin therapy, the current standard of care, or ticagrelor treatment, starting in the early postoperative period, and continuing for 2 years after cabg.

this clinical trial will be a randomized double-blind study focusing on ticagrelor antiplatelet therapy as a means of improving vein graft patency after cabg. patients will be eligible if they have received at least 1 vein bypass graft at time of surgery. patients will be randomized to receive either aspirin 81 mg bid or ticagrelor 90 mg bid. the aspirin and ticagrelor medications will be prepared in blinded capsules. patients recovering from surgery will be eligible for study randomization within the first 5 postoperative days. treatment will continue for 1 year, at which time patients will undergo a ct coronary angiogram to assess graft patency. patients will then be invited to continue participating in the trial for 1 more year, and a repeat ct coronary angiogram will be performed at the 2 year postoperative time-point.

Eligibility criteria:
inclusion criteria: 1. provision of informed consent prior to any study specific procedures 2. female and/or male patients aged 18-90 years 3. patients undergoing first-time cabg with at least 1 saphenous vein graft, irrespective of concurrent valve surgery exclusion criteria: 1. inability to provide informed consent 2. pregnancy or seeking pregnancy 3. patients undergoing redo-cabg 4. serum creatinine \>1.8 mg/dl (need for contrast with ct coronary angiogram) 5. hypersensitivity or allergy to aspirin or ticagrelor 6. anticipated need for postoperative anticoagulation with coumadin, dabigatran or rivaroxaban (mechanical valve, chronic atrial fibrillation, dvt/pe) 7. history of gastrointestinal hemorrhage 8. active pathological bleeding 9. history of intracranial hemorrhage 10. severe hepatic impairment 11. current or anticipated use of strong cyp3a4 inhibitors (e.g. ketoconazole, clarithromycin, nefazadone, ritonavir, and atazanavir)

Keywords: saphenous vein graft disease coronary artery bypass graft surgery antiplatelet therapy coronary artery disease secondary prevention graft patency
video-stylet for nasotracheal intubation

Conditions: Intubation, Difficult

Summary: the purpose of this study is to compare conventional laryngoscopy with video-stylet (trachway) for nasotracheal intubation in patients undergoing oro-maxillo-facial surgery.


Eligibility criteria:
inclusion criteria: 1. patients with american society of anesthesiologists physical status i-iii 2. aged 20-65 years 3. requiring nasotracheal intubation under general anesthesia 4. unlimited mouth open 5. unlimited neck motion exclusion criteria: 1. mouth open \< 3 cm 2. ankylosing arthritis patients. 3. bmi≧35 kg/m2

Keywords: conventional laryngoscopy , video-stylet , nasotracheal intubation
humidity under continuous positive airway pressure

Conditions: Sleep Apnea, Obstructive

Summary: heated humidification in cpap therapy is often not enough to prevent side effects like dryness of nasal mucosa and xerostomia, especially in cases of mouth breathing or mask leakage. additionally a higher level of humidification in lower ambient room temperature can lead to condensation and irritating noises. compliance of affected patients decreases considerably. regarding this, devices with humidifier and additional heated tubing are developed to automatically regulate optimal humidification and temperature right up to the mask. the efficacy of a system with controlled heated humidification and heated tubing in nasal masks under various conditions like leakage and different pressure levels is object of this study.

participants will breath 3 hours during daytime with a nasal mask under three different humidity modes (no humidity, controlled heated humidification, controlled heated humidification with heated tubing) with cpap 8 and 12 mmhg and with and without leakage. the ambient room temperature is controlled with air conditioning. changes in temperature and humidity is measured inside of the mask with a humidity sensor and recorded. after each phase the participants subjective opinion about humidity and temperature is asked.

Eligibility criteria:
inclusion criteria: * age 20-70 * obstructive sleep apnoea syndrome exclusion criteria: * other severe acute or chronic nasal disease (rhinitis, sinusitis), cardiovascular disease, respiratory or neurologic disease * incapable of giving consent

Keywords: obstructive sleep apnea humidification mask heated tubing
intubating conditions during rapid sequence induction in elderly with either suxamethonium 1.0 mg/kg or rocuronium 1.0 mg/kg

Conditions: Intubation Conditions

Summary: the aim of this study is to determine the proportion of excellent tracheal intubation conditions at 60 seconds after administration of either rocuronium 1.0 mg/kg or suxamethonium 1 mg/kg in patients with age ≥ 80 years during rapid sequence induction.

elderly patients are frail and susceptible to complications in the perioperative period. they are at higher risk of major morbidity and mortality and are characterized by a reduction in cardiac output, liver function and renal function. these physiological changes influence pharmacodynamics and pharmacokinetics of drugs administered during anesthesia as for example neuromuscular blocking agents (nmba). the number of elderly patients (\>80 years) is increasing and a large proportion of these patients will require surgery and anesthesia with employment of rapid sequence induction (rsi) within the next decades. rsi and intubation is performed when there is an increased risk of pulmonary aspiration of gastric contents. because of its fast onset time succinylcholine is often used to facilitate tracheal intubation during rsi. however, succinylcholine has certain side effects such as cardiac arrhythmia, hyperkalemia, muscle soreness, short duration of action and shorter time to desaturation. it is therefore unknown if succinylcholine 1.0 mg/kg provides better intubating conditions compared to high dose rocuronium (1.0 mg/kg) in the elderly. in this matter, there remains a need for a study to investigate the optimal muscle relaxant during rapid sequence induction for facilitating tracheal intubation in the elderly.

Eligibility criteria:
inclusion criteria: * age ≥ 80 * scheduled for surgery under general anesthesia with indication for rapid sequence induction * american society of anesthesiologists physical status classification (asa) i to iv * informed consent (see appendix 1) * body mass index (bmi) \< 35 kg/m2 * read and understand danish exclusion criteria: * neuromuscular disease * known allergy to rocuronium and/or suxamethonium * known hyperkalemia \> 5 mm * previous malignant hyperthermia * known homozygote plasmacholinesterase gene mutation variant a or s * known impaired kidney function defined as estimated glomerular filtration rate (egfr) \< 30
low-dose combination of mycophenolate mofetil (mmf) and tacrolimus (tac) for refractory lupus nephritis

Conditions: Lupus Nephritis

Summary: a trial of combination of two drugs for the treatment of refractory lupus nephritis.

low-dose combination of mycophenolate mofetil and tacrolimus for refractory lupus nephritis: a 12-month prospective study

Eligibility criteria:
inclusion criteria: 1. active nephritis documented by renal biopsy within 24 months of entry; 2. failure to respond to 2 or more immunosuppressive regimens which consisted of high-dose prednisolone combined with other non-corticosteroid immunosuppressive agents together with ace inhibitors plus or minus angiotensin receptor blockers (arb) for at least 4 months for each regimen at the maximally tolerated drug dosages; 3. serum creatinine (scr) less than 200umol/l. exclusion criteria: 1. previous intolerance to either mmf/tac; 2. scr \>200umol/l; 3. informed consent unavailable.

Keywords: lupus nephritis glomerulonephritis nephropathy refractory
micronutrient status involved in immunity in elderly patients with covid-19

Conditions: Covid19

Summary: during the ongoing covid-19 pandemic, age was clearly the major factor of mortality. increasing age was strongly associated with this risk, with the upper 80 years age group having more than 12-fold increased risk compared with those aged 50-59 years. male gender was also associated with a doubling of risk. the elderly subject is particularly exposed to global denutrition with risk of micronutrients deficiencies such as vitamins and trace elements. those deficits expose to lower immunity. in addition, viral infection as covid-19 can also worsen these deficits. in general, low levels or intakes of micronutrients such as zn, se and vitamin a have been associated with adverse clinical outcomes during viral infections. this notion has been confirmed in a recent review proposing that besides vitamins a and d also b vitamins, vitamin c, omega-3 polyunsaturated fatty acids, as well as selenium, zinc and iron should be considered in the assessment of micronutrients in covid-19 patients. in this context, the microcovaging study will evaluate copper, zinc and selenium, vitamin a, d and e status in elderly subjects affected by covid- 19 and to correlate this status with prognosis of this disease.


Eligibility criteria:
inclusion criteria: * hospitalized adult patient ≥ 50 years at the time of admission, * suffering from confirmed covid-19 (positive quantitative pcr for sars-cov-2 and/or chest scanner suggestive of covid-19), * informed and non-opposed to the research. patient will be informed of the study by his medical doctor during hospitalization or by post thanks to a generic information sheet dedicated to covid-19 researches. exclusion criteria: * adult patient \< 50 years at the time of admission * negative quantitative pcr for sars-cov-2

Keywords: covid19 micronutriments elderly
reducing hemarthrosis in tibial tubercle osteotomy by the administration of intravenous tranexamic acid

Conditions: Tibial Tubercle Osteotomy

Summary: the purpose of the proposed study is to evaluate the effects of administering intravenous tranexamic acid (txa) to patients undergoing high tibial osteotomy (hto) and tibial tubercle osteotomy (tto) to minimize hemarthrosis within the knee joint and post operative pain and swelling.

not provided

Eligibility criteria:
inclusion criteria: * patients undergoing tto * age 18-60 * willing and able to provide consent exclusion criteria: * legally incompetent or mentally impaired (e.g., minors, alzheimer's subjects, dementia, etc.) * younger than 18 years of age * older than 60 years of age * any patient considered a vulnerable subject * have bleeding or clotting disorder * preoperative anticoagulation therapy * abnormal coagulation profile * renal disorder or insufficiency * sickle cell disease

Keywords: tibial tubercle osteotomy tranexamic acid
diagnosing and monitoring portal hypertension non-invasively using spleen stiffness measurement in patients with advanced chronic liver disease: a prospective cohort study

Conditions: Advanced Chronic Liver Disease

Summary: the goal of this observational study is to assess non-invasive tools' efficacy in predicting portal hypertension-related complications in individuals with advanced chronic liver disease. the main question it aims to answer are: - what are the cut-off values for non-invasive tests (nits) (including lsm, ssm) that predict the presence and occurrence of hepatic decompensation in individuals with advanced chronic liver disease? participants will undergo regular study visits involving non-invasive tests (lsm, ssm) and assessments to monitor hepatic decompensation over the study period.


Eligibility criteria:
inclusion criteria: * age above 18years old * advanced chronic liver disease (defined as lsm ≥ 10kpa) * ability to provide informed consent exclusion criteria: * transjugular intrahepatic portosystemic shunt * previous liver transplantation * abnormality of the porto-mesenteric system (portal vein thrombosis, splenic vein thrombosis, splenectomy, portal cavernomatous transformation, porto-caval shunts) * hematological malignancy
spectroscopic mri guided proton therapy in assessing metabolic change in pediatric patients with brain tumors

Conditions: Malignant Brain Glioma

Summary: this trial studies how well spectroscopic magnetic resonance imaging (mri) guided proton therapy works in assessing metabolic change in pediatric patients with brain tumors. the non-invasive imaging, such as spectroscopic mri may help to map the differences in tumor metabolism compared to healthy tissue without injection of any contrast agent.

primary objectives: i. to obtain spectroscopic (s)mri data from pediatric high grade glioma (hgg) patients before receiving standard of care radiation therapy (rt) and correlate baseline cho/naa ratios to recurrence patterns. (cohort 1, observational) ii. to assess the feasibility and safety of using smri to define proton therapy high dose (60gy) target volumes for treatment delivery. (cohort 2, intervention) secondary objectives: i. to evaluate how cho/naa defined radiation target volumes compare to standard of care radiation target volumes in size and resulting radiation delivery to adjacent normal tissue, by creating mock comparison rt plans for each patient. ii. to compare voxel-to-voxel changes in pre-treatment and post-treatment smri and evaluate as potential early predictor of tumor response/recurrence. iii. to evaluate smri as a tool in identifying pseudoprogression vs. true progression and correlate post-treatment smri metabolite ratios with histopathology if collected. iv. to report patterns of failure in relationship to the rt field (local, marginal, or distant), progression-free survival (pfs) and overall survival (os) among all patients. v. to report patient reported outcomes of health related quality of life (qol) during and after proton therapy for pediatric hgg. vi. to build a longitudinal tracking database including clinical data, imaging, and genomic molecular profiling for pediatric hgg treatment. outline: patients undergo smri prior to radiation therapy, at 1, 4, and 7 months after rt, and at the time of suspected recurrence.

Eligibility criteria:
inclusion criteria: * pathologically diagnosed high-grade glioma (world health organization \[who\] grade 3-4). patients with a radiographically diagnosed high-grade glioma may enroll prior to pathologic confirmation, but would be removed from study if pathology did not confirm the diagnosis of high-grade glioma. * primary tumor located within the supratentorial brain. * recommended to receive definitive radiation therapy. * able to receive mri scans. * both males and females, and members of all races and ethnic groups are eligible for this trial. exclusion criteria: * patients with pacemakers, non-titanium aneurysm clips, neurostimulators, cochlear implants, non-titanium metal in ocular structures, or other incompatible implants which makes mri safety an issue are excluded. * patients that have any significant medical illnesses that in the investigator's opinion cannot be adequately tolerate mri scan are excluded. * pathology demonstrated low-grade glioma or other benign or non-invasive brain tumor.
learning brushing using game elements in mobile phones apps

Conditions: Oral Hygiene; Dental Plaque; Children, Only; Dental Devices, Home Care; Motivation; Learning

Summary: the study aims to compare the efficacy of using gamification for oral hygiene in children at home environment.

subjects will be randomized into three groups: 1. the first group will receive a manual toothbrush curaprox 5460 ultra soft, jordan miracle flossers floss, curaprox toothpaste 1450 and mobile phone application chomper chums. 2. the second group will receive electric toothbrush playbrush smart sonic, jordan miracle flossers floss, curaprox toothpaste 1450 and mobile phone application playbrush app. 3. the third group will receive electric toothbrush playbrush smart sonic, jordan miracle flossers floss, curaprox toothpaste 1450 and mobile phone application utoothia.

Eligibility criteria:
inclusion criteria: * children with secondary dentition (not completed); * children age 10 years and above and don't have mental or physical disabilities; * children brushing teeth by themselves; * children using manual or electric toothbrush; * children using a mobile phone; exclusion criteria: * children with the fixed orthodontic appliance; * children above 14 years;

Keywords: oral hygiene dental plaque brushing flossing gamification game elements motivation education children parents
safety of chlamydia vaccine cth522 in healthy women aged 18 to 45 years

Conditions: Chlamydia Trachomatis

Summary: the present trial is a phase i first in human, double blind, parallel and placebo controlled trial of ssi's adjuvanted chlamydia vaccine cth522: cth522-caf01 (caf01 is an adjuvant system) and cth522-al(oh)3. the trial will be conducted at imperial college research site in the united kingdom. subjects are randomly assigned to one of the following three treatment groups in a ratio of 3:3:1. this trial consisted of 10 visits and 5 telephonic interviews


Eligibility criteria:
inclusion criteria: 1. is a healthy female between 18 and 45 years of age on the day of first trial vaccination 2. has provided signed informed consent 3. is willing and likely to comply with the trial procedures 4. is prepared to grant authorised persons access to their medical record 5. willing to use acceptable contraceptive measures\* during the trial (2 weeks before and 2 weeks after the trial) * heterosexually active female capable of becoming pregnant must (in addition to requiring male partner to use condoms) agree to use hormonal contraception, or to complete abstinence, from at least 2 weeks before the first vaccination until at least 2 weeks after the last. (note: periodic abstinence \[e.g. calendar, ovulation, symptothermal, post-ovulation methods\] and withdrawal and intrauterine device or intrauterine hormone releasing system and progestogen-only oral hormonal contraception, where inhibition of ovulation is not the primary mode of action, are not acceptable methods of contraception) exclusion criteria: 1. has confirmed history of pelvic inflammatory disease or significant gynaecological diseases 2. is positive for c. trachomatis (pcr) 3. is positive for gonorrhoea (urine), hiv, hepatitis b/c, syphilis (blood) 4. has a positive pregnancy test 5. has a significant active disease - such as cardiac, liver, immunological, neurological, psychiatric; or clinically significant abnormality of haematological or biochemical parameters. 6. has bmi of 35 kg/m2 or greater 7. is currently participating in another clinical trial with an investigational or noninvestigational drug or device 8. has received, or plans to receive, an active immunisation within 14 days of the start of the trial or any of the immunisation visits in this trial 9. is currently receiving treatment with immunosuppressive agents e.g. oral, inhaled, nasal or injected corticosteroids. (topical steroids are allowed, unless applied to the im injection site.) 10. is using an intrauterine device 11. has a condition which in the opinion of the investigator is not suitable for participation in the trial 12. known or confirmed allergy to any of the vaccine constituents -

Keywords: safety immunogenicity phase i
effects of sulforaphane on normal prostate tissue

Conditions: Prostate Cancer

Summary: the investigators proposed to identify the biological effects of a high-sulforaphane broccoli sprout extract in normal prostate tissue. the investigators hypothesize that consumption of high-sulforaphane broccoli sprout extract every other day will inhibit growth of prostate cancer cells.


Eligibility criteria:
inclusion criteria: * men aged 40-75 years * low or intermediate grade prostate cancer (as defined by gleason sum less than or equal to 7) and clinical stage t1 or t2 * serum prostate specific antigen less than 20 ng/ml * have elected radical prostatectomy, brachytherapy or active surveillance as their primary treatment exclusion criteria: * no current physician diagnosed disease (including but not limited to): kidney disease requiring dialysis, cognitive deficits, substance abuse * bmi \ 40 kg/m2 * use of any hormonal treatments, including but not limited to testosterone * any previous cancer diagnosis or treatment within the previous five years, excluding non-melanoma skin cancer * inability or unwillingness to eat a diet that is free of brassica vegetables for the duration of the study * use of any dietary supplements other than a multivitamin (including herbal preparations) * allergy to cruciferous vegetables or any of the specific fillers used in the placebo * usual consumption of \> 5 servings per week of brassica vegetables
development of a screening tool to detect and stage cachectic cancer patients

Conditions: Cachexia

Summary: the aim of the study is to develop a screenings tool that will enable hospital nurses to detect and stage cancer cachectic patients. the early detection and staging of cancer cachexia will assist the oncology team in providing the cachectic cancer patient tailor-made patient care.

in this cross-sectional study, the participants will complete 4 times a set of questionnaires and measurements. the data that will be collected is: age; sex; height; weight; type of tumour; classification of malignant tumours (tnm); progression of tumour and used therapy; blood sample to analyse albumin, creatine, hemoglobin, ldh and crp; use of parental nutrition; dietary assessment; use of nutritional supplements; quality of life by using the eortc-qlq; subjective global assessment; presence of percutaneous endoscopic gastrostomy; use of enteral or parenteral nutrition; body composition based on a bio impedance assessment; hand grip strength and mid upper arm circumference. based on all these data points a easy to use tool/score for a hospital setting will be created. during the first assessment the measurements will be done in the morning and the evening to test the reproducibility.

Eligibility criteria:
inclusion criteria: * new diagnosed patients with primary head and neck cancer neoplasms * new diagnosed patients with metastatic pancreatic neoplasms * new diagnosed patients with metastatic colonic neoplasms exclusion criteria: * patients with other primary neoplasms * patients already in therapy * patients with non-metastatic colonic or pancreatic neoplasms